Afatinib as a Potential Therapeutic Option for Patients With NSCLC With EGFR G724S

Afatinib as a Potential Therapeutic Option for Patients With NSCLC With EGFR G724S

Introduction: EGFR G724S has been described to mediate resistance to first- and third-generation EGFR tyrosine kinase inhibitors (TKIs). In vitro experiments have provided compelling evidence that G724S retains sensitivity for afatinib. Nevertheless, limited data have reported the clinical efficacy...

Full description

Bibliographic Details
Main Authors: Yang Wei, MD, Benyuan Jiang, PhD, Shulin Liu, MD, Zhonghan Zhang, MD, Wenfeng Fang, PhD, Yunpeng Yang, PhD, Xin Li, MD, Jingyi Zhao, MD, Hongyun Zhao, PhD
Format: Article
Language:English
Published: Elsevier 2021-07-01
Series:JTO Clinical and Research Reports
Subjects:
EGFR G724S
EGFR 19 deletion
Non–small Cell Lung Cancer
Afatinib
Online Access:http://www.sciencedirect.com/science/article/pii/S2666364321000527

Internet

http://www.sciencedirect.com/science/article/pii/S2666364321000527

Similar Items